ASCO: ‘Any way you slice’ it, Arcellx’s CAR-T is matching J&J-Legend’s Carvykti, analyst says
Arcellx took a risk by including more patients with a tougher, more aggressive form of multiple myeloma in an early-stage trial for its CAR-T med. But it doesn’t matter, because “any way you slice” it, the small biotech seems to have put up strong enough data to rival the market-leading therapy by Johnson & Johnson and Legend Biotech.
Maryland-based Arcellx presented the latest on CART-ddBCMA, its BCMA-specific CAR-modified T-cell therapy for multiple myeloma, at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Friday.
The data comes from a phase 1 study of patients with relapsed or refractory multiple myeloma, including 31 eligible for an efficacy and safety analysis who had at least three prior lines of treatment. Out of these patients, 21 had “poor prognostic factors,” including extramedullary disease, which means cancer that has spread to form tumors outside the bone marrow in the soft tissues of the body.
Read the full article at: www.fiercebiotech.com
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
